US Patent

US7300931 — Compositions for treating cell proliferation disorders

Composition of Matter · Assigned to Kinex Pharmaceuticals LLC · Expires 2030-12-28 · 5y remaining

Vulnerability score 10/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects compounds and methods for treating cell proliferation disorders.

USPTO Abstract

The invention relates to compounds and methods for treating cell proliferation disorders.

Drugs covered by this patent

Patent Metadata

Patent number
US7300931
Jurisdiction
US
Classification
Composition of Matter
Expires
2030-12-28
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Kinex Pharmaceuticals LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.